ReviewIn vitro models2022
In vitro models and ex vivo systems used in inflammatory bowel disease.
Review in In vitro models, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Microbially derived glutathione from Eubacterium rectale alleviates oxidative stress and promotes intestinal epithelial recovery.Microbiome · 2026Article
- Ryanodine Receptor 1 Is Dispensable for CD4European journal of immunology · 2026Article
- In vitro modeling of inflammatory bowel diseases using a newly developed immunocompetent colon epithelial monolayer co-culture model.npj biomedical innovations · 2026Article
- The dual roles of natural cannabidiol in combating oxidative stress and inflammation: A potential intestinal guardian.Redox biology · 2026Review
- Polysaccharides and the colon mucus barrier: a review of biophysical interactions and functional impacts.NPJ science of food · 2026Review
- Process Optimisation, Pharmaceutical Characterisation, and in vitro Activity of Mesalamine Nanocrystals in PMA-differentiated THP-1 cell Lines in the Late Inflammatory and Profibrotic Phase.AAPS PharmSciTech · 2026Article
- Theranostic Probiotic Engineered Living Materials That Dynamically Respond to Inflammation Markers.Advanced healthcare materials · 2026Article
- Three-dimensional multicellular layer structure: an advanced in vitro model for studying inflammatory bowel diseases.Scientific reports · 2025Article
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- In Vitro and Ex Vivo Models to Study Molecular Trafficking Across the Human Intestinal Barrier.International journal of molecular sciences · 2025Review
- Detection of tissue colonizing bacteria and their association with clinicopathological and molecular features of inflammatory bowel disease.Journal of translational medicine · 2025Article
- From AI-AssistedPharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring the omnigenic architecture of selected complex traits.American journal of human genetics · 2025Article
- A scalable human gut-immune co-culture model for evaluating inflammatory bowel disease anti-inflammatory therapies.SLAS discovery : advancing life sciences R & D · 2025Article
- Development of the Gut Microbial Immune and Epithelial Cellular System (GutMICS) to Investigate the Immunological Role of Gut Anaerobes.Biotechnology and bioengineering · 2025Article
- Retinoic Acid Modulates Immune Differentiation in a Human Small Intestinal In Vitro Model.Cells · 2025Article
- Gastrointestinal tract, its pathophysiology andWorld journal of gastroenterology · 2025Review
- Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model.BMC complementary medicine and therapies · 2025Article
- Nanoencapsulation enhanced the performance of β-carotene for ameliorating inflammation in patient-derived organoids.Nanomedicine (London, England) · 2025Article
- Thrombin-preconditioned mesenchymal stromal cell-derived extracellular vesicles attenuate experimental necrotizing enterocolitis.Stem cell research & therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal condition. Ulcerative colitis and Crohn's disease are types of inflammatory bowel disease. Over many decades, the disease has been a topic of study, with experts still trying to figure out its cause and pathology. Researchers have established many in vivo animal models, in vitro cell lines, and ex vivo systems to understand its cause ultimately and adequately identify a therapy. However, in vivo animal models cannot be regarded as good models for studying IBD since they cannot completely simulate the disease. Furthermore, because species differences are a crucial subject of concern, in vitro cell lines and ex vivo systems can be employed to recreate the condition properly. In vitro models serve as the starting point for biological and medical research. Ex vivo and in vitro models for replicating gut physiology have been developed. This review aims to present a clear understanding of several in vitro and ex vivo models of IBD and provide insights into their benefits and limits and their value in understanding intestinal physiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.